Skip to content

The Evaluation of Functional Parenchymal Volume and Split Renal Function Before and After Partial Nephrectomy

3D Assessment of Functional Parenchymal Volume and Split Renal Function Before and After Partial Nephrectomy

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04798963
Enrollment
60
Registered
2021-03-16
Start date
2021-03-02
Completion date
2022-03-02
Last updated
2021-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal Cell Carcinoma

Keywords

kidney cancer, partial nephrectomy, split renal function

Brief summary

The study aims to compare pre- and postoperative 3D renal function results of patients who underwent on-clamp and off-clamp partial nephrectomy.

Interventions

PROCEDUREOn-clamp partial nephrectomy

Partial nephrectomy will performed with renal artery clamping (less than or equal to 25 minutes)

Partial nephrectomy will performed without renal artery clamping

Sponsors

I.M. Sechenov First Moscow State Medical University
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1\. Men and women \>18 years; 2. Diagnosis of unilateral renal cell carcinoma (stage T1-T3aN0M0); 3. Planned surgery: retroperitoneoscopic/laparoscopic/robotic partial nephrectomy; 4. Patients with CT of the kidneys with contrast enhancement performed according to the required protocol. \-

Exclusion criteria

1. Age \< 18 years old or ASA\> 3; 2. Solitary kidney; 3. Bilateral kidney 4. The presence of concomitant systemic pathology (DM, AH), as well as kidney disease (glomerulonephritis), which can change the state of the renal parenchyma; 5. Obstructive nephropathy 6. Systemic intake of nephrotoxic drugs; 7. Pregnancy. -

Design outcomes

Primary

MeasureTime frame
GFR after the surgery6 months

Secondary

MeasureTime frame
Complication rate (Clavien-Dindo)3 months

Countries

Russia

Contacts

Primary ContactDmitry Fiev, M.D., Ph.D.
fiev@mail.ru+79265690949
Backup ContactDmitry Enikeev, M.D., Ph.D.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026